AN LC–ESI-MS/MS METHOD DEVELOPMENTAND ITS VALIDATIONFOR THE QUANTIFICATION OF PRALSETINIB IN K2EDTA HUMANPLASMA
Open Access
- 7 September 2025
- journal article
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 285-291
Abstract
Objective: Aim of the work is to developa simple LC-ESI-MS/MS approach for a sensitive, specific, and quantitative determination of pralsetinib in human K2EDTA plasma. Methods: The samples were separated using an isocratic mobile phase made up of 0.1%HCOOH, methanol and acetonitrile in 10:70:20(% v/v) fractions. In multiple reaction monitoring mode, mass transitions for pralsetinib were m/z 534.27/302.19 and for asciminib internal standard, they were 450.1/257.10 in positive ionization mode. Results: Linearity and a high r2 value (>0.99) characterize the calibration curve, which spans 141.5–5660 ng/ml. Theintra-batchaccuracywaswithin-8.44 to 5.69% relative errorandtheprecisionwaswithin3.14 to 4.92%. Theinter-batchaccuracywaswithin-5.26 to 4.63% relative error and the precision was within 3.32 to 4.93%. The extraction recoveries executed at three quality control levels and their mean recovery was 97.45%. Conclusion: In conclusion, a new approach to evaluating pralsetinib in human K2EDTA plasma has been approved for use in clinical, bioavailability, and bioequivalence investigations, and it may be used to quantify pralsetinib.Keywords
This publication has 23 references indexed in Scilit:
- Validation of an LC–MS/MS method for quantitation of fostemsavir in plasmaJournal of Pharmacological and Toxicological Methods, 2023
- Development of a fast, online three-phase electroextraction hyphenated to fast liquid chromatography–mass spectrometry for analysis of trace-level acid pharmaceuticals in plasmaAnalytica Chimica Acta, 2022
- A high-throughput, ultrafast, and online three-phase electro-extraction method for analysis of trace level pharmaceuticalsAnalytica Chimica Acta, 2021
- New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1)Current Oncology Reports, 2020
- RET fusions in solid tumorsCancer Treatment Reviews, 2019
- Pharmacokinetic studies of a novel tubulin inhibitor SK1326 in rat plasma by UPLC–MS/MSBiomedical Chromatography, 2019
- Precision Targeted Therapy with BLU-667 for RET-Driven CancersCancer Discovery, 2018
- Peer Reviewed: Sample Preparation for LC/MS/MS: Analyzing Biological and Environmental SamplesAnalytical Chemistry, 1998
- Determination of saquinavir in human plasma, saliva, and cerebrospinal fluid by ion-pair high-performance liquid chromatography with ultraviolet detectionJournal of Chromatography B: Biomedical Sciences and Applications, 1997
- Activation of a novel human transforming gene, ret, by DNA rearrangementCell, 1985